{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:26:41Z","timestamp":1772166401157,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81273961"],"award-info":[{"award-number":["No. 81273961"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81303117"],"award-info":[{"award-number":["No. 81303117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81273961"],"award-info":[{"award-number":["No. 81273961"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81303117"],"award-info":[{"award-number":["No. 81303117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China tonghua guhong pharmaceutical co.LTD."},{"name":"China tonghua guhong pharmaceutical co.LTD.","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Coronary microvascular disease (CMVD) can be described as one of the cardiovascular diseases with normal coronary angiography but evidence of myocardial ischemia or microcirculatory lesions, often presenting as angina pectoris attacks. Coronary artery microtubular dysfunction is one of the pathogenic features of coronary heart disease, but its occurrence and development and the current CMVD-intervention therapy needs further research. Chinese traditional medicine (TCM) has advantages for the treatment of cardiovascular diseases. Hence, this article describes an ongoing randomized controlled clinical trial based on the theory of TCM for the purpose of evaluating the efficacy and safety of\n                      <jats:italic>Guhong<\/jats:italic>\n                      injection versus placebo in patients with CMVD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>This is a multicenter, randomized, parallel-arm, open-label, double-blind, placebo-controlled clinical trial. A total of 260 eligible patients will be allocated and randomly assigned, in a ratio of 1:1, to either the experimental group or the control group. The treatment course is 10 consecutive days, and with an 8-week follow-up. The primary outcome is therapeutic efficacy. Secondary outcomes include the quantitative score of TCM syndromes (a series of TCM symptoms and signs of coronary heart disease), the average frequency of anginal attacks, electrocardiogram (ECG) changes, inflammatory response, endothelial function indicators and myocardial metabolites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      This trial is strictly designed in accordance with principles and regulations issued by the China Food and Drug Administration (CFDA). The results should provide high-quality evidence on the efficacy and safety of\n                      <jats:italic>Guhong<\/jats:italic>\n                      injection in the treatment of CMVD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Chinese Clinical Trials Registry, ID:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=38437\">ChiCTR1900022902<\/jats:ext-link>\n                      . Registered on 27 April 2019.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-019-3990-3","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T08:02:48Z","timestamp":1578902568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of Guhong injection for treating coronary microvascular disease: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Zhuang","family":"Jieqin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Shuling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai","family":"Hairong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Xingzhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yanhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zilin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Bojun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"3990_CR1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/eurheartj\/ehr331","volume":"33","author":"L Jespersen","year":"2012","unstructured":"Jespersen L, Hvelplund A, Abildstr\u00f8m SZ, et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33:734\u201344.","journal-title":"Eur Heart J"},{"issue":"10","key":"3990_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.4244\/EIJV12I10A197","volume":"12","author":"CJ Vrints","year":"2016","unstructured":"Vrints CJ, Haine SE. Prevention of coronary microvascular plugging: the next target in STEMI? EuroIntervention. 2016;12(10):1201\u20132.","journal-title":"EuroIntervention"},{"issue":"11","key":"3990_CR3","doi-asserted-by":"publisher","first-page":"e80342","DOI":"10.1371\/journal.pone.0080342","volume":"8","author":"S Zhang","year":"2013","unstructured":"Zhang S, Zhao Y, Xu M, et al. FoxO3a modulates hypoxia stress induced oxidative stress and apoptosis in cardiac microvascular endothelial cells. PLoS One. 2013;8(11):e80342.","journal-title":"PLoS One"},{"key":"3990_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fcvm.2017.00081","volume":"4","author":"DC Tong","year":"2018","unstructured":"Tong DC, Whitbourn R, MacIsaac A, et al. High-sensitivity C-reactive protein is a predictor of coronary microvascular dysfunction in patients with ischemic heart disease. Front Cardiovasc Med. 2018;4:81.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"3990_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.echo.2015.09.001","volume":"29","author":"K Kakuta","year":"2016","unstructured":"Kakuta K, Dohi K, Sato Y, et al. Chronic inflammatory disease is an independent risk factor for coronary flow velocity reserve impairment unrelated to the processes of coronary artery calcium deposition. J Am Soc Echocardiogr. 2016;29(2):173\u201380.","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"3990_CR6","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1161\/ATVBAHA.116.307293","volume":"36","author":"A Honda","year":"2016","unstructured":"Honda A, Tahara N, Nitta Y, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose-positron emission tomography\/computed tomography is associated with endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2016;36(9):1980\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"3990_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nrcardio.2015.72","volume":"12","author":"J Dean","year":"2015","unstructured":"Dean J, Cruz SD, Mehta PK, et al. Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. Nat Rev Cardiol. 2015;12(7):406\u201314.","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"3990_CR8","first-page":"32","volume":"21","author":"J Jin","year":"2019","unstructured":"Jin J, Zhao Y, Fu JX. Modern clinical application of blood-activating and stasis-removing drugs in coronary heart disease. J Liaoning Univ Tradit Chin Med. 2019;21(8):32\u20135.","journal-title":"J Liaoning Univ Tradit Chin Med"},{"issue":"09","key":"3990_CR9","first-page":"58","volume":"14","author":"B Xie","year":"2018","unstructured":"Xie B, Lu YJ, Yan M. Literature textual research of the Chinese medicinal Redflower. Asia Pacific Tradit Med. 2018;14(09):58\u201360.","journal-title":"Asia Pacific Tradit Med"},{"issue":"9","key":"3990_CR10","first-page":"78","volume":"8","author":"ZR Han","year":"2006","unstructured":"Han ZR. Clinical observation of 136 cases of coronary heart disease angina pectoris treated by Guhong injection. Chin J Mod Med. 2006;8(9):78.","journal-title":"Chin J Mod Med"},{"issue":"12","key":"3990_CR11","first-page":"2405","volume":"25","author":"XX Jiang","year":"2019","unstructured":"Jiang XX, Zhao WW. The research progress in the mechanism and diagnosis of coronary microvascular disease. Med Recapitulate. 2019;25(12):2405\u201310.","journal-title":"Med Recapitulate"},{"issue":"64","key":"3990_CR12","first-page":"136","volume":"9","author":"XP Chen","year":"2019","unstructured":"Chen XP. Clinical effect analysis of Guhong injection on coronary heart disease. World Latest Med Inf (Electronic Version). 2019;9(64):136.","journal-title":"World Latest Med Inf (Electronic Version)"},{"issue":"4","key":"3990_CR13","first-page":"245","volume":"4","author":"National Health and Pharmaceutical Bureau of China","year":"1988","unstructured":"National Health and Pharmaceutical Bureau of China. Guidelines for clinical research on cardiovascular drugs. Chin J Clin Pharmacol. 1988;4(4):245\u201354.","journal-title":"Chin J Clin Pharmacol"},{"key":"3990_CR14","first-page":"69","volume-title":"Guiding principles of clinical research on Chinese medicine for treatment of coronary heart disease and angina pectoris","author":"XY Zheng","year":"2002","unstructured":"Zheng XY. Guiding principles of clinical research on Chinese medicine for treatment of coronary heart disease and angina pectoris. Beijing: China Medical Science and Technology Press; 2002. p. 69\u201370."},{"issue":"3","key":"3990_CR15","doi-asserted-by":"publisher","first-page":"e0119980","DOI":"10.1371\/journal.pone.0119980","volume":"10","author":"B Gigante","year":"2015","unstructured":"Gigante B, Strawbridge RJ, Velasquez IM, et al. Analysis of the role of interleukin 6 receptor haplo-types in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease. PLoS One. 2015;10(3):e0119980.","journal-title":"PLoS One"},{"issue":"1","key":"3990_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/ehjcvp\/pvv036","volume":"2","author":"LA Fortuna","year":"2016","unstructured":"Fortuna LA, Pawloski PA, Parker ED, et al. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events. Eur Heart J Cardiovasc Pharmacother. 2016;2(1):13\u20139.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"3990_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/CRD.0b013e318283f65a","volume":"21","author":"TM Kolettis","year":"2013","unstructured":"Kolettis TM, Barton M, Langleben D, et al. Endothelin in coronary artery disease and myocardial infarction. Cardiol Rev. 2013;21(5):249\u201356.","journal-title":"Cardiol Rev"},{"issue":"21","key":"3990_CR18","first-page":"5459","volume":"36","author":"XF Wang","year":"2016","unstructured":"Wang XF, Cui SY, Ye ZX. Research progress on the role of nitric oxide in the pathogenesis of atherosclerosis. Chin J Gerontol. 2016;36(21):5459\u201362.","journal-title":"Chin J Gerontol"},{"issue":"04","key":"3990_CR19","first-page":"316","volume":"33","author":"XS Yang","year":"2018","unstructured":"Yang XS, Sun FY, Li ZB. The value of nitric oxide, et-1 and homocysteine in the diagnosis of coronary heart disease. Lab Med. 2018;33(04):316\u201320.","journal-title":"Lab Med"},{"issue":"1","key":"3990_CR20","first-page":"431","volume":"73","author":"EJ Wasserman","year":"2006","unstructured":"Wasserman EJ, Shipley NM. Atherothrombosis in acute coronary syndromes mechanisms, markers, and mediators of vulnerability. Mt Sinai J Med. 2006;73(1):431\u20139.","journal-title":"Mt Sinai J Med"},{"issue":"10","key":"3990_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1503\/cmaj\/051291","volume":"173","author":"L Babllim","year":"2005","unstructured":"Babllim L, Jaffea S. Troponin, the biomarker of choice for the detection of cardiac injury. CMAJ. 2005;173(10):1191\u20133.","journal-title":"CMAJ"},{"issue":"17","key":"3990_CR22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/eurheartj\/eht513","volume":"35","author":"F Crea","year":"2014","unstructured":"Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35(17):1101\u201311.","journal-title":"Eur Heart J"},{"issue":"02","key":"3990_CR23","first-page":"247","volume":"28","author":"WY Xiao","year":"2019","unstructured":"Xiao WY, Huang HM, Feng LL. New research progress of coronary microvascular dysfunction. J Cardiovasc Rehabil Med. 2019;28(02):247\u201351.","journal-title":"J Cardiovasc Rehabil Med"},{"key":"3990_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.curtheres.2010.02.001","volume":"71","author":"YQ Zhong","year":"2010","unstructured":"Zhong YQ, Fu JJ, Liu XM, et al. The reporting quality, scientific rigor, and ethics of randomized placebo controlled trials of traditional Chinese medicine compound formulations and the differences between Chinese and non-Chinese trials. Curr Ther Res Clin E. 2010;71:30\u201349.","journal-title":"Curr Ther Res Clin E"},{"key":"3990_CR25","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3990-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-019-3990-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3990-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T03:20:13Z","timestamp":1627356013000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3990-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3990"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3990-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13551\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13551\/v2","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"20 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol, ICF, and recruitment poster were reviewed and approved by the Ethics Committee of the Guangdong Provincial Hospital of Traditional Chinese Medicine (No. BF2018\u2013180-01), the Ethics Committee of the Guizhou Provincial Hospital of Traditional Chinese Medicine, the Ethics Committee of the Second Affiliated Hospital of Guizhou University of TCM, the Ethics Committee of the Foshan TCM Hospital, the Ethics Committee of the Shenzhen Longgang District Hospital of TCM, and the Ethics Committee of the Yangjiang People\u2019s Hospital. Written informed consent will be obtained from each participant prior to enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}